IPO
Development Programs to Focus on GI and Inflammation Therapies with Reduced, or No, Side Effects
Establishment of a debt financing plan for a maximum amount of 15 million euros, with IPF Partners
Reported Additional Positive Phase 2 Data Showing Ridinilazole Improved Quality of Life and Microbiome Preservation Compared to Standard of Care
Sydney, Australia, 10 October 2019: Recce Pharmaceuticals Ltd, developing a new class of synthetic antibiotics, is pleased to announce it has raised AU$6,768,444.28 in a placement to institutional, professional and sophisticated investors that will result in 26,032,478 fully paid ordinary shares being issued at AU$0.26 per share
Apogenix, a biopharmaceutical company developing next generation immuno-oncology therapeutics, announced that it will attend several upcoming international conferences.
Heidelberg Pharma AG reported on the first nine months of fiscal year 2019 and the Group’s financial figures.
Datavant, the leader in helping healthcare organizations connect and share health data, announced a series of corporate updates.
Global Blood Therapeutics, Inc., announced that on October 1, 2019, the compensation committee of GBT’s board of directors granted 12 new employees options to purchase an aggregate of 24,600 shares of the company’s common stock with a per share exercise price of $46.99 and restricted stock units for an aggregate of 57,050 shares of the company’s common stock.
Oxford start-up developing novel therapeutics based on deep expertise in immune cell regulation
Sareum Holdings plc, the specialised small molecule drug development business, will announce its results for the full year ended 30 June 2019 on Tuesday 15 October.
PRESS RELEASES